Tag Archives: GlaxoSmithKline

Spinoff Odds and Ends: Pfizer’s Consumer Business, La Quinta Award Winning Idea

Grab your cup of coffee and kick off the week with some Odds and Ends: Late last year, Pfizer (PFE) announced it was considering its ‘options’ for its consumer health division. The early buzz was all about a sale though and the maker of Advil and Centrum has since been running a sales process with a rumored desired… Read More »

GSK CEO Witty Still Not Interested In A Consumer Spinoff…For Now

With a diverse business portfolio and some enterprising competitors, GlaxoSmithKline (GSK) has been the subject of spinoff rumors for years. So far, the company has opted to not pursue any divestitures of that nature and that will remain the case for some time if CEO Andrew Witty has his way. Well…at least regarding the consumer unit. While discussing the… Read More »

The Spinoff Tease – Glaxo Scraps Plans For ViiV IPO

We have written about British pharma giant GlaxoSmithKline (GSK) a number of times over the past few years, but so far, none of the rumored spinoffs have ever come to fruition. It seems that will remain the case, as CEO Andrew Witty announced that the company would not be pursuing a spinoff of its HIV-centric Viiv. GSK owns over 80%… Read More »

GlaxoSmithKline CEO Witty: Open To Consumer Spinoff But No Current Plans

GlaxoSmithKline’s (GSK) CEO Sir Andrew Witty recently sat down with the Financial Times and the discussion included some talk about the future of its consumer health business. Although Mr. Witty mentioned that he is open to the idea of a spinoff at some point, the company was not currently pursuing the idea. There has been some spinoff speculation… Read More »

Glaxo Has No Current Plans To Spin Off Viiv, But Does Not Rule It Out

Whenever a corporate executive has to publicly state that they will not be spinning something off, it’s generally only a matter of time.  This is likely the case with GlaxoSmithKline(GSK) and its majority-owned Viiv Healthcare unit.  Viiv, of which Glaxo owns 76.5%, recently filed for approval for its anti-HIV drug, dolutegravir. If the drug is approved, it is… Read More »